Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
Status:
Not yet recruiting
Trial end date:
2027-07-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on
radiographic outcomes in pediatric participants with HPP who have not previously been treated
with asfotase alfa.